Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease
- PMID: 6319219
Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease
Abstract
Leukotriene B4, an arachidonic acid metabolite, is a potent chemotactic agent, and is thought to be an important mediator of inflammation. To investigate the role of this compound as a mediator of inflammation in inflammatory bowel disease, arachidonic acid was incubated with ionophore and colonic mucosa from patients with inflammatory bowel disease and from normal subjects. Mucosa from patients with inflammatory bowel disease converted 2.17% of exogenous arachidonate to leukotriene B4; mucosa from normal subjects converted 0.37%. The production of leukotriene was blocked by sulfasalazine. To determine if inflammatory bowel mucosa contained endogenous leukotriene B4, lipid extracts were analyzed by high pressure liquid chromatography. Mucosa from patients with inflammatory bowel disease contained 254 ng of leukotriene B4 per gram and mucosa from normal subjects contained less than 5 ng of leukotriene B4 per gram. The presence of significant amounts of leukotriene B4 in colonic mucosa in patients with inflammatory bowel disease, combined with the known biologic effects of leukotriene B4, suggests that it may be an important mediator of inflammation in inflammatory bowel disease.
Similar articles
-
Alteration of prostaglandin E2 and leukotriene B4 synthesis in chronic inflammatory bowel disease.Hepatogastroenterology. 1996 Nov-Dec;43(12):1508-12. Hepatogastroenterology. 1996. PMID: 8975956
-
[Leukotriene synthesis by gastrointestinal tissue and its pharmacologic modification].Wien Klin Wochenschr. 1986 Feb 21;98(4):98-104. Wien Klin Wochenschr. 1986. PMID: 3010577 German.
-
Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease.Gastroenterology. 1985 Jan;88(1 Pt 1):55-63. doi: 10.1016/s0016-5085(85)80132-3. Gastroenterology. 1985. PMID: 3917261
-
Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.Dan Med Bull. 1989 Sep;36(4):378-93. Dan Med Bull. 1989. PMID: 2572403 Review. No abstract available.
-
Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators.Agents Actions. 1992;Spec No:C22-6. doi: 10.1007/BF01996091. Agents Actions. 1992. PMID: 1359743 Review.
Cited by
-
Stereochemical Determination of Fistularins Isolated from the Marine Sponge Ecionemia acervus and Their Regulatory Effect on Intestinal Inflammation.Mar Drugs. 2021 Mar 22;19(3):170. doi: 10.3390/md19030170. Mar Drugs. 2021. PMID: 33809895 Free PMC article.
-
Release of leukotriene B4 and 5-hydroxyeicosatetraenoic acid during phagocytosis of artificial immune complexes by peripheral neutrophils in chronic inflammatory bowel disease.Clin Exp Immunol. 1986 Aug;65(2):465-71. Clin Exp Immunol. 1986. PMID: 3024887 Free PMC article.
-
Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils.Gut. 1987 Feb;28(2):181-5. doi: 10.1136/gut.28.2.181. Gut. 1987. PMID: 3030903 Free PMC article.
-
The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat.Br J Pharmacol. 1988 May;94(1):65-72. doi: 10.1111/j.1476-5381.1988.tb11500.x. Br J Pharmacol. 1988. PMID: 2840994 Free PMC article.
-
A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease.World J Gastroenterol. 2010 Sep 28;16(36):4504-14. doi: 10.3748/wjg.v16.i36.4504. World J Gastroenterol. 2010. PMID: 20857519 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
